AOD-9604

AOD-9604

Anti-Obesity Drug 9604 (HGH fragment 176-191)

HGH fragment — fat loss without GH side effects

Fat Loss ★ 73
Half-life
~30 minutes (SubQ)
Cycle
Long cycles tolerated — 12-16 weeks on, 4 weeks off. Receptor desensitization is minimal.
Storage
Lyophilized: freezer. Reconstituted: 2-8°C, 28 days.
Research
Phase 2b human trials completed (Metabolic Pharmaceuticals); did not advance to Phase 3. TGA-approved for compounding in Australia.

About

A 16-amino-acid fragment of HGH that retains the fat-burning action of growth hormone without the muscle-growth or blood-sugar effects. Reached Phase 2b trials by Metabolic Pharmaceuticals.

Mechanism

Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage) by activating β3-adrenergic receptors in adipocytes; does not affect IGF-1 or blood glucose.

Dosage

250 mcg
1x per day on empty stomach
0102030405060708090100

Draw to 10 units on a U-100 insulin syringe

5 mg · 2 mL BAC

Route
Subcutaneous (SubQ)
Duration
8-12 weeks

When to take: Best on an empty stomach in the morning. Avoid food for 90 min after to maximize lipolysis.

Reconstitution

Vial size (mg): 5 mg · BAC water (mL): 2 mL · Concentration: 2500 mcg/mL

Standard reconstitution. Often stacked with GH secretagogues for synergistic fat loss.

Benefits

  • Visceral and abdominal fat reduction
  • No effect on blood glucose or insulin
  • No effect on IGF-1 (safer for cancer history)
  • Joint-friendly (unlike full GH)
  • Well tolerated in clinical trials

Side effects

  • Generally very mild
  • Occasional injection-site irritation
  • Mild fatigue first week
  • No reported serious side effects in trials

Gender notes

Same dosing. Popular for stubborn belly fat after age 40.

Cautions

  • Pregnancy and breastfeeding (limited data)
  • Eating disorder history (caution with intentional fat loss)

Research

Stacks well with